IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v6y2022i2d10.1007_s41669-021-00307-1.html
   My bibliography  Save this article

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide

Author

Listed:
  • Dikshyanta Rana

    (University of Glasgow)

  • Claudia Geue

    (University of Glasgow)

  • Kelly Baillie

    (Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde)

  • Jiafeng Pan

    (University of Strathclyde)

  • Tanja Mueller

    (University of Strathclyde)

  • Jennifer Laskey

    (Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde)

  • Marion Bennie

    (University of Strathclyde
    Public Health Scotland)

  • Julie Clarke

    (Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde)

  • Robert J. Jones

    (Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde
    University of Glasgow)

  • Ailsa Brown

    (Healthcare Improvement Scotland)

  • Olivia Wu

    (University of Glasgow)

Abstract

Objective The aim was to assess the real-world healthcare resource use and direct medical costs for metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide, in whom chemotherapy is not yet indicated (pre-chemotherapy) or who had previously received docetaxel-based chemotherapy (post-chemotherapy), before commencing these medicines. Methods A retrospective cost analysis of mCRPC patients who commenced abiraterone or enzalutamide between 2012 and 2015 was conducted. Routinely collected datasets from the largest health board in Scotland and the UK, Greater Glasgow and Clyde, were linked. They contained information on patient demographics, diagnosis, outpatient consultations, hospital admissions, treatments (abiraterone and enzalutamide), and supportive medicines. Unit costs were obtained from the Scottish Health Service Costs, Personal Social Services Research Unit, and British National Formulary. Generalised linear model-based regression was used to estimate total mean direct costs, and two-part models were used to estimate separate cost components. All models were adjusted for propensity score and key variables. Sensitivity analysis was conducted to explore the impact of hypothetical patient access scheme discounts. Results Estimated total mean direct medical costs of treating mCRPC patients were similar, albeit with wide and overlapping confidence intervals. Across both treatments, patients who received abiraterone or enzalutamide in a pre-chemotherapy setting incurred the highest total mean direct medical costs. However, post-chemotherapy patients were associated with higher outpatient clinic visits, inpatient hospital admissions, and supportive medicines. Regarding relative contribution to the total mean direct medical cost, the treatment costs were the main contributor, followed by inpatient admissions, outpatient clinic visits, and supportive medicines. Conclusion The total mean direct medical costs were similar for abiraterone and enzalutamide patients. The costs were not driven by the choice of treatment regimen, but treatment setting (pre-chemotherapy or post-chemotherapy indications) and related healthcare resource utilisation. Future studies should focus on economic evaluations, such as cost-effectiveness analyses, using real-world data.

Suggested Citation

  • Dikshyanta Rana & Claudia Geue & Kelly Baillie & Jiafeng Pan & Tanja Mueller & Jennifer Laskey & Marion Bennie & Julie Clarke & Robert J. Jones & Ailsa Brown & Olivia Wu, 2022. "Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide," PharmacoEconomics - Open, Springer, vol. 6(2), pages 303-313, March.
  • Handle: RePEc:spr:pharmo:v:6:y:2022:i:2:d:10.1007_s41669-021-00307-1
    DOI: 10.1007/s41669-021-00307-1
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-021-00307-1
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-021-00307-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Glick, Henry A. & Doshi, Jalpa A. & Sonnad, Seema S. & Polsky, Daniel, 2014. "Economic Evaluation in Clinical Trials," OUP Catalogue, Oxford University Press, edition 2, number 9780199685028, Decembrie.
    2. Claudia Geue & James Lewsey & Paula Lorgelly & Lindsay Govan & Carole Hart & Andrew Briggs, 2012. "Spoilt For Choice: Implications Of Using Alternative Methods Of Costing Hospital Episode Statistics," Health Economics, John Wiley & Sons, Ltd., vol. 21(10), pages 1201-1216, October.
    3. Borislava Mihaylova & Andrew Briggs & Anthony O'Hagan & Simon G. Thompson, 2011. "Review of statistical methods for analysing healthcare resources and costs," Health Economics, John Wiley & Sons, Ltd., vol. 20(8), pages 897-916, August.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Matthew Franklin & James Lomas & Simon Walker & Tracey Young, 2019. "An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 37(5), pages 631-643, May.
    2. Tor Iversen & Eline Aas & Gunnar Rosenqvist & Unto Häkkinen & on behalf of the EuroHOPE study group, 2015. "Comparative Analysis of Treatment Costs in EUROHOPE," Health Economics, John Wiley & Sons, Ltd., vol. 24(S2), pages 5-22, December.
    3. Noemi Kreif & Richard Grieve & Rosalba Radice & Zia Sadique & Roland Ramsahai & Jasjeet S. Sekhon, 2012. "Methods for Estimating Subgroup Effects in Cost-Effectiveness Analyses That Use Observational Data," Medical Decision Making, , vol. 32(6), pages 750-763, November.
    4. Maria Rubio-Valera & María Teresa Peñarrubia-María & Maria Iglesias-González & Martin Knapp & Paul McCrone & Marta Roig & Ramón Sabes-Figuera & Juan V. Luciano & Juan M. Mendive & Ana Gabriela Murruga, 2019. "Cost-effectiveness of antidepressants versus active monitoring for mild-to-moderate major depressive disorder: a multisite non-randomized-controlled trial in primary care (INFAP study)," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(5), pages 703-713, July.
    5. José-Manuel Pastora-Bernal & María-José Estebanez-Pérez & Guadalupe Molina-Torres & Francisco-José García-López & Raquel Sobrino-Sánchez & Rocío Martín-Valero, 2021. "Telerehabilitation Intervention in Patients with COVID-19 after Hospital Discharge to Improve Functional Capacity and Quality of Life. Study Protocol for a Multicenter Randomized Clinical Trial," IJERPH, MDPI, vol. 18(6), pages 1-12, March.
    6. Edward C. F. Wilson & Miranda Mugford & Garry Barton & Lee Shepstone, 2016. "Efficient Research Design," Medical Decision Making, , vol. 36(3), pages 335-348, April.
    7. Wendy Hens & Dirk Vissers & Nick Verhaeghe & Jan Gielen & Luc Van Gaal & Jan Taeymans, 2021. "Unsupervised Exercise Training Was Not Found to Improve the Metabolic Health or Phenotype over a 6-Month Dietary Intervention: A Randomised Controlled Trial with an Embedded Economic Analysis," IJERPH, MDPI, vol. 18(15), pages 1-13, July.
    8. Jun-Hui Wu & Yao Wu & Zi-Jing Wang & Yi-Qun Wu & Tao Wu & Meng-Ying Wang & Xiao-Wen Wang & Si-Yue Wang & Jia-Ting Wang & Huan Yu & Yong-Hua Hu, 2021. "Healthcare Costs Associated with Complications in Patients with Type 2 Diabetes among 1.85 Million Adults in Beijing, China," IJERPH, MDPI, vol. 18(7), pages 1-10, April.
    9. Zhiyuan Hou & Ellen Van de Poel & Eddy Van Doorslaer & Baorong Yu & Qingyue Meng, 2014. "Effects Of Ncms On Access To Care And Financial Protection In China," Health Economics, John Wiley & Sons, Ltd., vol. 23(8), pages 917-934, August.
    10. Caballer-Tarazona, Vicent & Guadalajara-Olmeda, Natividad & Vivas-Consuelo, David, 2019. "Predicting healthcare expenditure by multimorbidity groups," Health Policy, Elsevier, vol. 123(4), pages 427-434.
    11. Joel Smith & Helen Banks & Harry Campbell & Anne Douglas & Eilidh Fletcher & Alison McCallum & Tron Anders Moger & Mikko Peltola & Sofia Sveréus & Sarah Wild & Linda J. Williams & John Forbes & on beh, 2015. "Parameter Heterogeneity In Breast Cancer Cost Regressions – Evidence From Five European Countries," Health Economics, John Wiley & Sons, Ltd., vol. 24(S2), pages 23-37, December.
    12. NamKwen Kim & Kyung-Min Shin & Eun-Sung Seo & Minjung Park & Hye-Yoon Lee, 2020. "Electroacupuncture with Usual Care for Patients with Non-Acute Pain after Back Surgery: Cost-Effectiveness Analysis Alongside a Randomized Controlled Trial," Sustainability, MDPI, vol. 12(12), pages 1-13, June.
    13. José Leal & Stefania Manetti & James Buchanan, 2018. "The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study," PharmacoEconomics, Springer, vol. 36(10), pages 1263-1272, October.
    14. Toni Mora & Joan Gil & Antoni Sicras-Mainar, 2012. "The Influence of BMI, Obesity and Overweight on Medical Costs: A Panel Data Approach," Working Papers 2012-08, FEDEA.
    15. Jay Dev Dubey, 2021. "Measuring Income Elasticity of Healthcare-Seeking Behavior in India: A Conditional Quantile Regression Approach," Journal of Quantitative Economics, Springer;The Indian Econometric Society (TIES), vol. 19(4), pages 767-793, December.
    16. Kaushik Ghosh & Irina Bondarenko & Kassandra L Messer & Susan T Stewart & Trivellore Raghunathan & Allison B Rosen & David M Cutler, 2020. "Attributing medical spending to conditions: A comparison of methods," PLOS ONE, Public Library of Science, vol. 15(8), pages 1-17, August.
    17. Claudia Schulz & Gisela Büchele & Raphael S. Peter & Dietrich Rothenbacher & Christian Brettschneider & Ulrich C. Liener & Clemens Becker & Kilian Rapp & Hans-Helmut König, 2021. "Health-economic evaluation of collaborative orthogeriatric care for patients with a hip fracture in Germany: a retrospective cohort study using health and long-term care insurance claims data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(6), pages 873-885, August.
    18. Fan Yang & Brenda Gannon & Andrew Weightman, 2018. "Public’s Willingness to Pay Towards a Medical Device for Detecting Foot Ulceration in People with Diabetes," Applied Health Economics and Health Policy, Springer, vol. 16(4), pages 559-567, August.
    19. Kurt Lavetti & Thomas DeLeire & Nicolas R. Ziebarth, 2023. "How do low‐income enrollees in the Affordable Care Act marketplaces respond to cost‐sharing?," Journal of Risk & Insurance, The American Risk and Insurance Association, vol. 90(1), pages 155-183, March.
    20. Kristina R. Dahlstrom & Shuangshuang Fu & Wenyaw Chan & Zeena Shelal & Lois M. Ramondetta & David R. Lairson, 2018. "Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients," PharmacoEconomics, Springer, vol. 36(11), pages 1355-1365, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:6:y:2022:i:2:d:10.1007_s41669-021-00307-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.